MiniMed 670G hybrid closed loop artificial pancreas system for the treatment of type 1 diabetes mellitus: overview of its safety and efficacy
Open accessThe DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
Introduction: Automated insulin delivery for people with type 1 diabetes has been a major goal in the diabetes technology field for many years. While a fully automated system has not yet been accomplished, the MiniMed™ 670G artificial pancreas (AP) system is the first commercially available insulin pump that automates basal insulin delivery, while still requiring user input for insulin boluses. Determining the safety and efficacy of this system is essential to the development of future devices striving for more automation.Areas Covered: This review will provide an overview of how the MiniMed 670G system works including its safety and efficacy, how it compares to similar devices, and anticipated future advances in diabetes technology currently under development.Expert Opinion: The ultimate goal of advanced diabetes technologies is to reduce the burden and amount of management required of patients with diabetes. In addition to reducing patient workload, achieving better glucose control and improving hemoglobin A1c (HbA1c) values are essential for reducing the threat of diabetes-related complications further down the road. Current devices come close to reaching these goals, but understanding the unmet needs of patients with diabetes will allow future technologies to achieve these goals more quickly.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
DiMeglio, L. A., Evans-Molina, C., & Oram, R. A. (2018) · The Lancet · doi:10.1016/s0140-6736(18)31320-5 · Cited by 1,561
Katsarou, A., Gudbjörnsdottir, S., Rawshani, A., Dabelea, D., Bonifacio, E., Anderson, B. J., Jacobsen, L. M., Schatz, D. A., & Lernmark, Å. (2017) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2017.16 · Cited by 1,475
Garg, S. K., Weinzimer, S. A., Tamborlane, W. V., Buckingham, B. A., Bode, B. W., Bailey, T. S., Brazg, R. L., Ilany, J., Slover, R. H., Anderson, S. M., et al. (2017) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2016.0421 · Cited by 585 · cited 2×
“analyze the safety of the MiniMed 670G system for use in T1D patients [12,14].”
MethodTanenbaum, M. L., Hanes, S. J., Miller, K. M., Naranjo, D., Bensen, R., & Hood, K. K. (2017) · Diabetes Care · doi:10.2337/dc16-1536 · Cited by 296 · cited 2×
“While not specific to the MiniMed 670G, Tanenbaum investigated barriers to device uptake among adults with T1D [22].”
BackgroundForlenza, G. P., Li, Z., Buckingham, B. A., Pinsker, J. E., Cengiz, E., Wadwa, R. P., Ekhlaspour, L., Church, M. M., Weinzimer, S. A., Jost, E., et al. (2018) · Diabetes Care · doi:10.2337/dc18-0771 · Cited by 246 · cited 2×
“When integrated with the Dexcom G6, this pump uses Basal-IQTM technology (Tandem Diabetes Care, San Diego, CA) to reduce occurrences of hypoglycemia through predictive low glucose suspend (PLGS), which is the same concept as suspend before low [15].”
MethodSelf-citationPala, L., Dicembrini, I., & Mannucci, E. (2019) · Acta Diabetologica · doi:10.1007/s00592-019-01326-5 · Cited by 112 · cited 1×
“comfort of injections for the patient [5].”
A clinical guide to advanced diabetes devices and closed-loop systems using the CARES paradigm
Messer, L. H., Berget, C., & Forlenza, G. P. (2019) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2019.0105 · Cited by 100 · cited 2×
“patients on the system, and relevant SENSOR/SHARING characteristics [17,40].”
BackgroundSelf-citation
Cited by
A Randomized Trial of Closed-Loop Control in Children with Type 1 Diabetes
Breton, M. D., Kanapka, L. G., Beck, R. W., Ekhlaspour, L., Forlenza, G. P., Cengiz, E., Schoelwer, M., Ruedy, K. J., Jost, E., Carria, L., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2004736 · Cited by 455
Self-citationA Systematic Review of Commercial Hybrid Closed-Loop Automated Insulin Delivery Systems
Peacock, S., Frizelle, I., & Hussain, S. (2023) · Diabetes Therapy · doi:10.1007/s13300-023-01394-5 · Cited by 122
Hybrid closed-loop insulin pump technology can be safely used in the inpatient setting
Pelkey, M. N., Boyle, M. E., Long, A., Castro, J. C., Cook, C. B., & Thompson, B. (2023) · Endocrine Practice · doi:10.1016/j.eprac.2022.11.006 · Cited by 25
Toffanin, C., Magni, L., & Cobelli, C. (2021) · IEEE Transactions on Medical Robotics and Bionics · doi:10.1109/tmrb.2021.3075775 · Cited by 22
Hybrid Closed-loop to Manage Gastroparesis in People With Type 1 Diabetes: a Case Series
Daly, A., Hartnell, S., Boughton, C. K., & Evans, M. (2021) · Journal of Diabetes Science and Technology · doi:10.1177/19322968211035447 · Cited by 23
Metadata
- Authors
- Saunders, A., Messer, L. H., & Forlenza, G. P.
- Venue
- Expert Review of Medical Devices
- Publisher
- Informa UK Limited
- Published
- 2019-09-30
- Volume
- 16
- Issue
- 10
- Pages
- 845-853
- ISSN
- 1743-4440 (ISSN-L)
- 1745-2422
- OpenAlex
- W2973516653
- Cited by
- 62
- References
- 7
- FWCI
- 5.51
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: MiniMed 670G hybrid closed loop artificial pancreas system for the treatment of type 1 diabetes mellitus: overview of its safety and efficacy. https://app.cochat.ai/papers/10.1080/17434440.2019.1670639
- The paper
- Saunders, A., Messer, L. H., & Forlenza, G. P. (2019). MiniMed 670G hybrid closed loop artificial pancreas system for the treatment of type 1 diabetes mellitus: overview of its safety and efficacy. Expert Review of Medical Devices. https://doi.org/10.1080/17434440.2019.1670639
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.